Skip to main navigation

Community
Science
Careers
- Life at Rhythm
- Working at Rhythm
About
- Senior Management
- Board of Directors
Investor Relations
Contact Us

INVESTOR RELATIONS

Overview
Events & Presentations
Stock Information
SEC Filings
Corporate Governance
News
Contact IR

News

Year

November 15, 2021

Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

November 9, 2021

Rhythm Pharmaceuticals to Present at Stifel 2021 Virtual Healthcare Conference

November 2, 2021

Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results

November 1, 2021

Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021

October 20, 2021

Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021

October 14, 2021

Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMCIVREE® (setmelanotide) for Bardet-Biedl and Alström Syndromes

October 14, 2021

Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Provides Updates on Uncovering Rare Obesity® Genetic Testing Program

September 22, 2021

Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting

September 21, 2021

Rhythm Pharmaceuticals Announces Marketing Authorisation of ▼IMCIVREE® (setmelanotide) in Great Britain

September 20, 2021

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (setmelanotide) for the treatment of obesity and control of hunger in Bardet-Biedl and Alström Syndromes

September 8, 2021

Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

September 2, 2021

Rhythm Pharmaceuticals Announces CMO Transition

September 2, 2021

Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference

August 12, 2021

Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting

August 5, 2021

Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference

August 3, 2021

Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results

August 3, 2021

Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

July 29, 2021

Rhythm Pharmaceuticals Announces Senior Leadership Additions

July 28, 2021

Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome

July 27, 2021

Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021

July 23, 2021

Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

July 22, 2021

Rhythm Pharmaceuticals and Medison Pharma Partner to Commercialize IMCIVREE™ (setmelanotide) in Israel

May 27, 2021

Rhythm Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

May 21, 2021

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunger Associated with POMC, PCSK1 and LEPR Deficiency

May 5, 2021

Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference

May 3, 2021

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

April 7, 2021

Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

March 20, 2021

Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021

March 9, 2021

Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021

March 1, 2021

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

February 24, 2021

Rhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference

February 10, 2021

Rhythm Pharmaceuticals, Inc. Announces Closing of $172.5 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 4, 2021

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

February 3, 2021

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

January 26, 2021

Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities

January 19, 2021

Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts

January 5, 2021

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

RHYTHM

Contact Us

Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116

COMMUNITY

SCIENCE

MC4R Pathway
Our Research
Our Pipeline
Our Focus
Clinical Studies
Expanded Access
Publications and Presentations
GOLD Academy
Glossary

CAREERS

Life at Rhythm
Working at Rhythm

ABOUT

Senior Management
Board of Directors

INVESTORS & MEDIA

Overview
Events and Presentations
Stock Information
SEC Filings
Corporate Governance
News
Contact IR

© 2021 Rhythm Pharmaceuticals, Inc. All Rights Reserved.
Rhythm, GOLD Academy, LEAD for Rare Obesity, Uncommon Obesity, Uncovering Rare Obesity, and their corresponding logos are trademarks of Rhythm Pharmaceuticals, Inc.

Terms of Use Privacy Policy